Psychedelics & Cannabis

Explore the complex interaction of cannabis and psychosis, and the sociocultural stressors and resulting neurobehavioral symptoms.

In this CME article, learn more about the best practices for engaging patients in the informed consent process for psychedelic treatment and psychedelic-assisted psychotherapy.

From the brain-gut connection to neurocognitive and neuropsychiatric symptoms of long COVID, here are highlights from the week in Psychiatric Times.

A phase 2A trial recently received confirmation to proceed in investigating psilocybin-assisted psychotherapy in the treatment of adult patients with IBS.

Psychiatry: a field of medicine that is constantly evolving.

From research updates on at-home ketamine use to the effects of comorbid depression and anxiety on insomnia treatment, here are highlights from the week in Psychiatric Times.

Should cannabis be regulated in the United States in a manner similar to alcohol and tobacco?

"If we ignore or do not successfully address these future risks, we may need more than luck to avoid these looming disasters."

From the relationship between social media and self-diagnosis to the FDA approval of the first treatment for agitation associated with Alzheimer disease dementia, here are highlights from the week in Psychiatric Times.

"It is essential to have an aggressive path forward to increase public awareness of mental health and illness, education on early intervention and treatment access, and continued destigmatization of mental illness."

One psychiatrist recounts his experience with ketamine.

The second coming of psychedelics… what will the outcome be?

From an update on at-home ketamine therapy to the psychopharmacologic treatment of bipolar depression, here are highlights from the week in Psychiatric Times.

The Future of Mental Health: Ketamine Therapy Report revealed that 55% of Americans who tried at home ketamine took more than the recommended dose.

Catch up on the latest CMEs in Psychiatric Times.

From special issues in diagnosing and treating catatonia to helping justice-involved individuals re-enter the community, here are highlights from the week in Psychiatric Times.

The agency’s conclusions are based on regulatory oversight needed to manage risks associated with CBD and other cannabis-derived products.

SPL026 with supportive therapy sees positive results in patients with major depressive disorder.

Remember to keep the cart behind the horse while practicing medicine.

Revisiting the CME articles featured in Psychiatric Times in 2022.

Selections from the 2022 Psychiatric Times cover features.

From current treatments for cannabis use disorder to new possibilities for the treatment of dementia, here are highlights from the week in Psychiatric Times.

While there are no FDA-approved medications available for CUD, some studies show potential off-label utility in mitigating withdrawal and maintaining abstinence. Learn more in this CME article.

From an in-depth analysis of ADHD in clinical practice to differences in effectiveness between intravenous and intranasal ketamine, here are highlights from the week in Psychiatric Times.